SCM
BCRX icon

Sarissa Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sarissa Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,094,168
Closed -$6.76M – 11
2024
Q2 		$6.76M Hold
1,094,168
– – 1.14% 8
2024
Q1 		$5.56M Buy
1,094,168
+94,168
+9% +$530K 0.97% 8
2023
Q4 		$5.99M Buy
1,000,000
+225,000
+29% +$1.3M 0.92% 7
2023
Q3 		$5.49M Hold
775,000
– – 0.74% 8
2023
Q2 		$5.46M Hold
775,000
– – 0.54% 9
2023
Q1 		$6.46M Sell
775,000
-205,288
-21% -$1.98M 0.83% 8
2022
Q4 		$11.3M Sell
980,288
-410,502
-30% -$5.12M 1.34% 7
2022
Q3 		$17.5M Hold
1,390,790
– – 1.98% 8
2022
Q2 		$14.7M Hold
1,390,790
– – 1.48% 8
2022
Q1 		$22.6M Sell
1,390,790
-2,648,810
-66% -$42.5M 2.14% 7
2021
Q4 		$55.9M Buy
4,039,600
+112,900
+3% +$1.49M 4.84% 7
2021
Q3 		$56.4M Sell
3,926,700
-334,300
-8% -$5.27M 4.43% 6
2021
Q2 		$67.4M Sell
4,261,000
-3,376,700
-44% -$45.9M 5.36% 7
2021
Q1 		$77.7M Sell
7,637,700
-537,300
-7% -$5.54M 7.45% 6
2020
Q4 		$60.9M Buy
8,175,000
+3,314,000
+68% +$17.1M 6.22% 8
2020
Q3 		$16.7M Buy
4,861,000
+3,786,000
+352% +$16.2M 1.97% 9
2020
Q2 		$5.12M Buy
+1,075,000
New +$4.29M 0.57% 10

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Sarissa Capital Management's BCRX Position: Q3 2024 in Review

Sarissa Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 1,094,168 shares — an estimated $6.76M sold.

Sarissa Capital Management first reported a position in BCRX in Q2 2020 and held it in 17 quarters. The position peaked at $77.7M in Q1 2021. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • Sarissa Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Sarissa Capital Management sold 1,094,168 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $6.76M.
  • Sarissa Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 17 quarters.
  • Sarissa Capital Management's BioCryst Pharmaceuticals position peaked at $77.7M in Q1 2021.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on Sarissa Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.